5,6-dichloro-2-trifluoromethyl-1H-benzimidazole | 2338-25-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并咪唑类
• 英文名称: 5,6-dichloro-2-trifluoromethyl-1H-benzimidazole
• 英文别名: 5,6-Dichlor-2-trifluormethyl-benzimidazol；2-Trifluormethyl-5,6-dichlor-benzimidazol；5,6-dichloro-2-trifluoromethyl-benzimidazole；5,6-Dichloro-2-(trifluoromethyl)-1H-benzimidazole
• CAS: 2338-25-2
• 化学式: C₈H₃Cl₂F₃N₂
• 分子量: 255.026
• InChiKey: KUMRUFFLHYXFLV-UHFFFAOYSA-N

物化性质

• 熔点：
  239-241 °C
• 沸点：
  337.8±42.0 °C(Predicted)
• 密度：
  1.672±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4
• 重原子数：
  15
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  28.7
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 海关编码：
  2933990090
• 危险标志：
  GHS07
• 危险性描述：
  H319
• 危险性防范说明：
  P305 + P351 + P338

反应信息

• 作为反应物：
  描述：

  5,6-dichloro-2-trifluoromethyl-1H-benzimidazole 在 溴 作用下， 以 水 为溶剂， 反应 24.0h， 以87%的产率得到4,7-Dibromo-5,6-dichloro-2-trifluoromethylbenzimidazole
  参考文献：
  名称：

  Polyhalogenobenzimidazoles: synthesis and Their inhibitory activity against casein kinases

  摘要：

  A series of novel polyhalogenated benzimidazoles have been prepared by exhaustive bromination of a variety of 2-substituted benzimidazoles. The efficacy of both new compounds and a number of their previously described cognates as inhibitors of casein kinases CK1, CK2 and G-CK was investigated. The type of N-1 alkyl substituent as well as introduction of a polyfluoroalkyl moiety at position 2 did not markedly influence the inhibitory efficacy toward CK2 of the respective 4,5,6,7-tetra-bromobenzimidazole derivatives which conversely were almost ineffective toward CK1 and G-CK. However, 4,5,6,7-tetra-bromobenzimidazoles substituted at position 2 with either chlorine, bromine or sulfur atom, while manifesting a still considerable inhibitory activity against CK2 (IC50 in the 0.49-0.93 muM range) proved to be potentially powerful inhibitors also against CK1 (IC50 in the 18.4-2.2 muM range). (C) 2003 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/s0968-0896(03)00403-6
• 作为产物：
  描述：

  4,5-二氯邻苯二胺 在 三氟乙酸 作用下， 以 水 、 乙酸乙酯 为溶剂， 生成 5,6-dichloro-2-trifluoromethyl-1H-benzimidazole
  参考文献：
  名称：

  Method of treating parastic protozoa with substituted benzimidazoles

  摘要：

  本发明涉及使用以下公式（I）所示的苯并咪唑类化合物：##STR1## 其中X.sup.1、X.sup.2、X.sub.3、X.sup.4、R.sup.3和R.sup.5按文中描述，这些化合物是用于对抗寄生原虫的药剂，特别是球虫。

  公开号：

  US05482956A1

文献信息

• Synthesis of Novel Halogenated Heterocycles Based on o-Phenylenediamine and Their Interactions with the Catalytic Subunit of Protein Kinase CK2
  作者：Maria Winiewska-Szajewska、Agnieszka Monika Maciejewska、Elżbieta Speina、Jarosław Poznański、Daniel Paprocki

  DOI：10.3390/molecules26113163

  日期：——

  Protein kinase CK2 is a highly pleiotropic protein kinase capable of phosphorylating hundreds of protein substrates. It is involved in numerous cellular functions, including cell viability, apoptosis, cell proliferation and survival, angiogenesis, or ER-stress response. As CK2 activity is found perturbed in many pathological states, including cancers, it becomes an attractive target for the pharma

  蛋白激酶CK2是高度多效性蛋白激酶，能够磷酸化数百种蛋白底物。它涉及许多细胞功能，包括细胞活力，凋亡，细胞增殖和存活，血管生成或ER应激反应。由于发现CK2活性在包括癌症在内的许多病理状态中受到干扰，因此它成为该药的有吸引力的靶标。已经开发了许多低质量的ATP竞争性抑制剂，其中大多数已被卤化。我们测试了六种系列卤代杂环配体的结合，这些配体衍生自可商购的4,5-二卤代苯-1,2-二胺。选择这些配体系列以使支架作用与直接归因于卤素原子存在的疏水相互作用分离。最初使用计算机分子对接技术来测试每种配体在CK2的ATP结合位点结合的能力。将HPLC衍生的配体疏水性数据与通过小体积差示扫描荧光法（nanoDSF）评估的结合亲和力进行比较。我们确定了三个有希望的配体支架，其中两个尚未被描述为CK2抑制剂，但可能导致有效的CK2激酶抑制剂。已经确定了在nanoDSF分析中被鉴定为最有前途的八种化合物对CK
• PARASITICIDAL COMPOSITIONS COMPRISING BENZIMIDAZOLE DERIVATIVES, METHODS AND USES THEREOF
  申请人：MERIAL LIMITED

  公开号：US20130281392A1

  公开（公告）日：2013-10-24

  The invention relates to oral, topical or injectable compositions for combating liver fluke parasites in mammals, comprising at least one benzimidazole derivative active agent. The invention also provides for an improved method for eradicating and controlling liver fluke parasite infections and infestations in a mammal comprising administering the compositions of the invention to the mammal in need thereof.

  该发明涉及用于对抗哺乳动物体内肝吸虫寄生虫的口服、局部或注射组合物，包括至少一种苯并咪唑衍生物活性剂。该发明还提供了一种改进的方法，用于根除和控制哺乳动物体内肝吸虫寄生虫感染和寄生，包括向需要的哺乳动物体内施用该发明的组合物。
• NOVEL HETEROCYCLIC COMPOUND
  申请人：DAEWOONG PHARMACEUTICAL CO., LTD.

  公开号：US20170088551A1

  公开（公告）日：2017-03-30

  The present invention relates to a compound represented by chemical formula 1, which can be used for the prevention and treatment of diseases caused by abnormality in a prolyl-tRNA synthetase (PRS) activity, or a pharmaceutically acceptable salt thereof, a method for preparing the same, and a pharmaceutical composition comprising the same.

  本发明涉及一种化学式1所代表的化合物，可用于预防和治疗由脯氨酰-tRNA合成酶（PRS）活性异常引起的疾病，或其药用盐，以及制备该化合物的方法和包含该化合物的药物组合物。
• Method for introducing amino groups into benzimidazole or
  申请人：Eli Lilly and Company

  公开号：US04031107A1

  公开（公告）日：1977-06-21

  The present invention is a process for the introduction of a nucleophilic group into a benzimidazole or imidazo[4,5-b or c]pyridine ring, which comprises treating a derivative of the corresponding 1-hydroxybenzimidazole or -imidazo[4,5-b or c]pyridine with a nucleophilic reagent. The process can also be used to reduce the 1-hydroxybenzimidazole or -imidazo[4,5-b or c]pyridine.

  本发明是一种将亲核基团引入苯并咪唑或咪唑[4,5-b或c]吡啶环的方法，包括将相应的1-羟基苯并咪唑或咪唑[4,5-b或c]吡啶衍生物与亲核试剂反应。该方法还可用于还原1-羟基苯并咪唑或咪唑[4,5-b或c]吡啶。
• Parasiticidal compositions comprising benzimidazole derivatives, methods and uses thereof
  申请人：Meng Charles Q

  公开号：US09000187B2

  公开（公告）日：2015-04-07

  The invention relates to oral, topical or injectable compositions for combating liver fluke parasites in mammals, comprising at least one benzimidazole derivative active agent. The invention also provides for an improved method for eradicating and controlling liver fluke parasite infections and infestations in a mammal comprising administering the compositions of the invention to the mammal in need thereof.

  本发明涉及口服、局部或注射用组合物，用于对抗哺乳动物体内的肝吸虫寄生虫，包括至少一种苯并咪唑衍生物活性剂。本发明还提供了一种改进的方法，用于根除和控制哺乳动物体内的肝吸虫寄生虫感染和寄生，包括向需要此类组合物的哺乳动物体内施用本发明的组合物。

表征谱图